


Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.58(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	08582/014002
		Serial No.	10/505,375
		Applicant	Fong et al.
		Filing Date	May 10, 2005
		Group	1632
		IDS Filed	January 23, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/JH/	Gene Therapy Advisory Committee, Seventh Annual Report, Health Departments of the United Kingdom, 2001.
↓	Kesari et al., "Therapy of Experimental Human Brain Tumors Using a Neuroattenuated Herpes Simplex Virus Mutant," <i>Lab. Invest.</i> 73(5):636-648, 1995.
↓	Letter from Dr. Margaret Straughan, Scientific Development & Bioethics Division, Department of Health, to Mr. Richard Clegg, regarding the publication date of the Seventh Annual Report of the Gene Therapy Advisory Committee dated April 30, 2007.
↓	MacKie et al., "Intralesional Injection of Herpes Simplex Virus 1716 in Metastatic Melanoma," <i>The Lancet</i> 357(9255):525-526, 2001.
↓	Third Party Observations Under Article 115 EPC Filed in Respect of European Patent Application No. 03743747.2 dated December 21, 2007.
↓	Wong et al., "Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma," <i>Human Gene Ther.</i> 12(3):253-265, 2001.

EXAMINER	/Joanne Hama/	DATE CONSIDERED	08/11/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			